# A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

> **NCT01031225** · PHASE2 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 113 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** STA 9090

## Key facts

- **NCT ID:** NCT01031225
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-02
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031225, "A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01031225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*